Lethal clinical outcome and chemotherapy and immunotherapy resistance in patients with urothelial carcinoma with MDM2 amplification or overexpression

Lethal clinical outcome and chemotherapy and immunotherapy resistance in patients with urothelial carcinoma with MDM2 amplification or overexpression

Background The E3 ubiquitin ligase murine double minute 2 (MDM2) binds the p53 transcriptional activation domain and acts as a potent inhibitor of TP53 pathway, one of the three most crucial oncogenic pathways in urothelial carcinoma (UC). However, the clinical significance and impact on tumor immun...

Full description

Saved in:
Bibliographic Details
Main Authors: Weijuan Zhang, Jiejie Xu, Hailong Liu, Yu Zhu, Zewei Wang, Han Zeng, Zhaopei Liu, Yuan Chang, Le Xu, Kaifeng Jin, Jingtong Xu, Xiaohe Su, Yawei Ding, Lingkai Zhang, Jiaxing Sun, Yuzhen Wu
Format: Article
Language:English
Published: BMJ Publishing Group 2025-01-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/1/e010964.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/13/1/e010964.full

Similar Items